A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine - PubMed (original) (raw)
Clinical Trial
doi: 10.1007/s00280-014-2674-7. Epub 2015 Jan 8.
Robert J Morgan, Shivaani Kummar, Jan H Beumer, M Suzette Blanchard, Christopher Ruel, Anthony B El-Khoueiry, Mary I Carroll, Jessie M Hou, Chun Li, Heinz J Lenz, Julie L Eiseman, James H Doroshow
Affiliations
- PMID: 25567350
- PMCID: PMC4344391
- DOI: 10.1007/s00280-014-2674-7
Clinical Trial
A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine, administered with tetrahydrouridine
Edward M Newman et al. Cancer Chemother Pharmacol. 2015 Mar.
Abstract
Purpose: Inhibitors of DNA (cytosine-5)-methyltransferases (DNMT) are active antineoplastic agents. We conducted the first-in-human phase I trial of 5-fluoro-2'-deoxycytidine (FdCyd), a DNMT inhibitor stable in aqueous solution, in patients with advanced solid tumors. Objectives were to establish the safety, maximum tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of FdCyd + tetrahydrouridine (THU).
Methods: FdCyd + THU were administered by 3 h IV infusion on days 1-5 every 3 weeks, or days 1-5 and 8-12 every 4 weeks. FdCyd was administered IV with a fixed 350 mg/m(2)/day dose of THU to inhibit deamination of FdCyd. Pharmacokinetics of FdCyd, downstream metabolites and THU were assessed by LC-MS/MS. RBC γ-globin expression was evaluated as a pharmacodynamics biomarker.
Results: Patients were enrolled on the 3-week schedule at doses up to 80 mg/m(2)/day without dose-limiting toxicity (DLT) prior to transitioning to the 4-week schedule, which resulted in an MTD of 134 mg/m(2)/day; one of six patients had a first-cycle DLT (grade 3 colitis). FdCyd ≥40 mg/m(2)/day produced peak plasma concentrations >1 µM. Although there was inter-patient variability, γ-globin mRNA increased during the first two treatment cycles. One refractory breast cancer patient experienced a partial response (PR) of >90 % decrease in tumor size, lasting over a year.
Conclusions: The MTD was established at 134 mg/m(2) FdCyd + 350 mg/m(2) THU days 1-5 and 8-12 every 4 weeks. Based on toxicities observed over multiple cycles, good plasma exposures, and the sustained PR observed at 67 mg/m(2)/day, the phase II dose for our ongoing multi-histology trial is 100 mg/m(2)/day FdCyd with 350 mg/m(2)/day THU.
Conflict of interest statement
Conflict of interest None.
Figures
Fig. 1
Partial response in a heavily pre-treated patient pre- and post-treatment CT scans of a 61-year-old female with metastatic breast cancer who had received multiple chemotherapy and hormonal regimens including high-dose chemotherapy and autologous stem cell transplant prior to enrolling on the phase I trial of FdCyd + THU
Fig. 2
Pharmacokinetics of FdCyd and its two major metabolites, FdUrd and FU a The maximum plasma concentrations of FdCyd, FdUrd, and FU are plotted as a function of the dose of FdCyd. Note the difference in scale between FdCyd (0–8000 ng/mL) and the metabolites (0–60 ng/mL). b Average FdCyd plasma concentration versus time profiles in patients after administration of 67 mg/m2 FdCyd (triangle N = 7), 100 mg/m2 FdCyd (square N = 16), and 133 mg/m2 FdCyd (circle N = 6). Samples with concentrations below LLQ were given a value of 0 for the purpose of this graph
Fig. 3
Relative fetal hemoglobin expression for the purpose of illustration, the data are normalized to each patient’s cycle 1 pre-treatment sample and presented as the mean of the normalized data for each dose level
Similar articles
- Concentrations of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU).
Beumer JH, Parise RA, Newman EM, Doroshow JH, Synold TW, Lenz HJ, Egorin MJ. Beumer JH, et al. Cancer Chemother Pharmacol. 2008 Jul;62(2):363-8. doi: 10.1007/s00280-007-0603-8. Epub 2007 Sep 26. Cancer Chemother Pharmacol. 2008. PMID: 17899082 Clinical Trial. - Oral and intravenous pharmacokinetics of 5-fluoro-2'-deoxycytidine and THU in cynomolgus monkeys and humans.
Holleran JL, Beumer JH, McCormick DL, Johnson WD, Newman EM, Doroshow JH, Kummar S, Covey JM, Davis M, Eiseman JL. Holleran JL, et al. Cancer Chemother Pharmacol. 2015 Oct;76(4):803-11. doi: 10.1007/s00280-015-2857-x. Epub 2015 Sep 1. Cancer Chemother Pharmacol. 2015. PMID: 26321472 Free PMC article. Clinical Trial. - Intravenous 5-fluoro-2'-deoxycytidine administered with tetrahydrouridine increases the proportion of p16-expressing circulating tumor cells in patients with advanced solid tumors.
Coyne GO', Wang L, Zlott J, Juwara L, Covey JM, Beumer JH, Cristea MC, Newman EM, Koehler S, Nieva JJ, Garcia AA, Gandara DR, Miller B, Khin S, Miller SB, Steinberg SM, Rubinstein L, Parchment RE, Kinders RJ, Piekarz RL, Kummar S, Chen AP, Doroshow JH. Coyne GO', et al. Cancer Chemother Pharmacol. 2020 May;85(5):979-993. doi: 10.1007/s00280-020-04073-5. Epub 2020 Apr 20. Cancer Chemother Pharmacol. 2020. PMID: 32314030 Free PMC article. Clinical Trial. - Pharmacokinetics, metabolism, and oral bioavailability of the DNA methyltransferase inhibitor 5-fluoro-2'-deoxycytidine in mice.
Beumer JH, Eiseman JL, Parise RA, Joseph E, Holleran JL, Covey JM, Egorin MJ. Beumer JH, et al. Clin Cancer Res. 2006 Dec 15;12(24):7483-91. doi: 10.1158/1078-0432.CCR-06-1250. Epub 2006 Nov 30. Clin Cancer Res. 2006. PMID: 17138702 - Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-5-Fluoro-2'-Deoxycytidine with Tetrahydrouridine in Solid Tumors.
Young CR, Adler S, Eary JF, Lindenberg ML, Jacobs PM, Collins J, Kummar S, Kurdziel KA, Choyke PL, Mena E. Young CR, et al. J Nucl Med. 2019 Apr;60(4):492-496. doi: 10.2967/jnumed.118.216994. Epub 2018 Nov 2. J Nucl Med. 2019. PMID: 30389817 Free PMC article. Clinical Trial.
Cited by
- Novel therapeutic agents in clinical trials: emerging approaches in cancer therapy.
Joshi DC, Sharma A, Prasad S, Singh K, Kumar M, Sherawat K, Tuli HS, Gupta M. Joshi DC, et al. Discov Oncol. 2024 Aug 11;15(1):342. doi: 10.1007/s12672-024-01195-7. Discov Oncol. 2024. PMID: 39127974 Free PMC article. Review. - Targeting DNA Methylation Machinery in Pediatric Solid Tumors.
Cristalli C, Scotlandi K. Cristalli C, et al. Cells. 2024 Jul 18;13(14):1209. doi: 10.3390/cells13141209. Cells. 2024. PMID: 39056791 Free PMC article. Review. - Nucleotide metabolism in cancer cells fuels a UDP-driven macrophage cross-talk, promoting immunosuppression and immunotherapy resistance.
Scolaro T, Manco M, Pecqueux M, Amorim R, Trotta R, Van Acker HH, Van Haele M, Shirgaonkar N, Naulaerts S, Daniluk J, Prenen F, Varamo C, Ponti D, Doglioni G, Ferreira Campos AM, Fernandez Garcia J, Radenkovic S, Rouhi P, Beatovic A, Wang L, Wang Y, Tzoumpa A, Antoranz A, Sargsian A, Di Matteo M, Berardi E, Goveia J, Ghesquière B, Roskams T, Soenen S, Voets T, Manshian B, Fendt SM, Carmeliet P, Garg AD, DasGupta R, Topal B, Mazzone M. Scolaro T, et al. Nat Cancer. 2024 Aug;5(8):1206-1226. doi: 10.1038/s43018-024-00771-8. Epub 2024 Jun 6. Nat Cancer. 2024. PMID: 38844817 Free PMC article. - Combined inhibition of histone deacetylase and cytidine deaminase improves epigenetic potency of decitabine in colorectal adenocarcinomas.
Tang Z, Liu L, Borlak J. Tang Z, et al. Clin Epigenetics. 2023 May 19;15(1):89. doi: 10.1186/s13148-023-01500-1. Clin Epigenetics. 2023. PMID: 37208732 Free PMC article. - The potential regulatory role of RNA methylation in ovarian cancer.
Zhao S, Zhang M, Zhu X, Xing J, Zhou J, Yin X. Zhao S, et al. RNA Biol. 2023 Jan;20(1):207-218. doi: 10.1080/15476286.2023.2213915. RNA Biol. 2023. PMID: 37194218 Free PMC article. Review.
References
- Lapeyre JN, Becker FF. 5-Methylcytosine content of nuclear DNA during chemical hepatocarcinogenesis and in carcinomas which result. Biochem Biophys Res Commun. 1979;87(3):698–705. - PubMed
- Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet. 2002;3(6):415–428. - PubMed
- Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R, Stone RM, Nelson D, Powell BL, DeCastro CM, Ellerton J, Larson RA, Schiffer CA, Holland JF. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol Res. 2002;20(10):2429–2440. - PubMed
- Kantarjian H, Issa JP, Rosenfeld CS, Bennett JM, Albitar M, DiPersio J, Klimek V, Slack J, de Castro C, Ravandi F, Helmer R, 3rd, Shen L, Nimer SD, Leavitt R, Raza A, Saba H. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer. 2006;106(8):1794–1803. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- U01CA099168/CA/NCI NIH HHS/United States
- P30CA033572/CA/NCI NIH HHS/United States
- UM1 CA186690/CA/NCI NIH HHS/United States
- P30 CA047904/CA/NCI NIH HHS/United States
- P30CA047904/CA/NCI NIH HHS/United States
- UM1CA186717/CA/NCI NIH HHS/United States
- N01-CM-52202/CM/NCI NIH HHS/United States
- U01CA062505/CA/NCI NIH HHS/United States
- UM1CA186690/CA/NCI NIH HHS/United States
- U01 CA062505/CA/NCI NIH HHS/United States
- U01 CA099168/CA/NCI NIH HHS/United States
- N01CM52202/CM/NCI NIH HHS/United States
- P30 CA033572/CA/NCI NIH HHS/United States
- UM1 CA186717/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials